Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin

Oncotarget

Volumn 7, Issue 5, 2016, Pages 5877-5891

  Wang, Yi Jun ^a   Huang, Yujian ^b   Anreddy, Nagaraju ^a   Zhang, Guan Nan ^a   Zhang, Yun Kai ^a   Xie, Meina ^a   Lin, Derrick ^b   Yang, Dong Hua ^a   Zhang, Mingjun ^b   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b The Ohio State University   (United States)

Author keywords

Biocompatibility; Drug delivery; Multidrug resistance; Tea nanoparticle; Tumor xenograft

Indexed keywords

DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; NANOCARRIER; NANOPARTICLE; TEA NANOPARTICLE; UNCLASSIFIED DRUG; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC ANTIBIOTIC; DRUG CARRIER; MULTIDRUG RESISTANCE PROTEIN; TEA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CANCER CELL; CONTROLLED STUDY; DIALYSIS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG POTENTIATION; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFUSION; ISOLATION PROCEDURE; MALE; MOUSE; MOUSE MODEL; MTT ASSAY; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATIC ELECTRICITY; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; CELL PROLIFERATION; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NUDE MOUSE; PATHOLOGY; TEA; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COLONIC NEOPLASMS; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, NUDE; NANOPARTICLES; P-GLYCOPROTEINS; TEA; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84958064216     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6711     Document Type: Article

References (55)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin. 2005; 55:10-30.
2. Cockerill GS, Lackey KE. Small molecule inhibitors of the class 1 receptor tyrosine kinase family. Curr Top Med Chem. 2002; 2:1001-1010.
3. Wang YJ, Zhang YK, Kathawala RJ, Chen ZS. Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. Cancers. 2014; 6:1925-1952.
4. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002; 53:615-627.
5. Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo-and xenobiotics by mammalian ATPbinding cassette multidrug resistance proteins. Physiol Rev. 2006; 86:849-899.
6. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005; 7: E118-33.
7. Ambudkar SV, Kim IW, Xia D, Sauna ZE. The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding. FEBS Lett. 2006; 580:1049-1055.
8. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976; 455:152-162.
9. Schinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJ, Borst P. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer. 1995; 31A:1295-1298.
10. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2:48-58.
11. Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev. 2006; 86:1179-1236.
12. Roskoski R Jr. STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun. 2003; 309:709-717.
13. Dean M, Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet. 2005; 6:123-142.
14. Sauna ZE, Smith MM, Muller M, Kerr KM, Ambudkar SV. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr. 2001; 33:481-491.
15. Wang YJ, Kathawala RJ, Zhang YK, Patel A, Kumar P, Shukla S, Fung KL, Ambudkar SV, Talele TT, Chen ZS. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochem Pharmacol. 2014; 90:367-378.
16. Matsuo K, Eno ML, Ahn EH, Shahzad MM, Im DD, Rosenshein NB, Sood AK. Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer. Am J Clin Oncol. 2011; 34:488-493.
17. Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J, Loos WJ, Wiemer EA, Mathijssen RH. Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res. 2011; 17:406-415.
18. Gao B, Russell A, Beesley J, Chen XQ, Healey S, Henderson M, Wong M, Emmanuel C, Galletta L, Johnatty SE, Bowtell D, Australian Ovarian Cancer Study Group, Haber M, et al. Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Sci Rep. 2014; 4:4669.
19. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecanpharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer. 2007; 110:138-147.
20. Strable E, Johnson JE, Finn M. Natural nanochemical building blocks: icosahedral virus particles organized by attached oligonucleotides. Nano letters. 2004; 4:1385-1389.
21. Zheng G, Chen J, Li H, Glickson JD. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci U S A. 2005; 102:17757-17762.
22. Mulder WJ, Strijkers GJ, Van Tilborg GA, Cormode DP, Fayad ZA, Nicolay K. Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc Chem Res. 2009; 42:904-914.
23. Huang Y, Wang Y, Wang Y, Yi S, Fan Z, Sun L, Lin D, Anreddy N, Zhu H, Schmidt M. Exploring naturally occurring ivy nanoparticles as an alternative biomaterial. Acta biomaterialia. 2015.
24. Xia L, Lenaghan SC, Zhang M, Zhang Z, Li Q. Naturally occurring nanoparticles from English ivy: an alternative to metal-based nanoparticles for UV protection. J Nanobiotechnology. 2010; 8:12-3155-8-12.
25. Wang Y, Sun L, Yi S, Huang Y, Lenaghan SC, Zhang M. Naturally occurring nanoparticles from arthrobotrys oligospora as a potential immunostimulatory and antitumor agent. Advanced Functional Materials. 2013; 23:2175-2184.
26. Zhang M, Liu M, Prest H, Fischer S. Nanoparticles secreted from ivy rootlets for surface climbing. Nano letters. 2008; 8:1277-1280.
27. Favi PM, Yi S, Lenaghan SC, Xia L, Zhang M. Inspiration from the natural world: from bio-adhesives to bio-inspired adhesives. J Adhes Sci Technol. 2014; 28:290-319.
28. Cormode DP, Jarzyna PA, Mulder WJ, Fayad ZA. Modified natural nanoparticles as contrast agents for medical imaging. Adv Drug Deliv Rev. 2010; 62:329-338.
29. Jankun J, Selman SH, Swiercz R, Skrzypczak-Jankun E. Why drinking green tea could prevent cancer. Nature. 1997; 387:561.
30. Paschka AG, Butler R, Young CY. Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate. Cancer letters. 1998; 130:1-7.
31. Negishi H, Xu JW, Ikeda K, Njelekela M, Nara Y, Yamori Y. Black and green tea polyphenols attenuate blood pressure increases in stroke-prone spontaneously hypertensive rats. J Nutr. 2004; 134:38-42.
32. Chen H, Zhang M, Qu Z, Xie B. Antioxidant activities of different fractions of polysaccharide conjugates from green tea (Camellia Sinensis). Food Chemistry. 2008; 106:559-563.
33. Fassina G, Buffa A, Benelli R, Varnier OE, Noonan DM, Albini A. Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent. Aids. 2002; 16:939-941.
34. Khan SG, Katiyar SK, Agarwal R, Mukhtar H. Enhancement of antioxidant and phase II enzymes by oral feeding of green tea polyphenols in drinking water to SKH-1 hairless mice: possible role in cancer chemoprevention. Cancer Res. 1992; 52:4050-4052.
35. Chen C, Yu R, Owuor ED, Kong AT. Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res. 2000; 23:605-612.
36. Wynder EL, Rose DP, Cohen LA. Nutrition and prostate cancer: a proposal for dietary intervention. Nutr Cancer. 1994; 22:1-10.
37. Pianetti S, Guo S, Kavanagh KT, Sonenshein GE. Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res. 2002; 62:652-655.
38. Yi S, Wang Y, Huang Y, Xia L, Sun L, Lenaghan SC, Zhang M. Tea Nanoparticles for Immunostimulation and Chemo-Drug Delivery in Cancer Treatment. J Biomed Nanotechnol. 2014; 10:1016-1029.
39. Nemzek J, Bolgos G, Williams B, Remick D. Differences in normal values for murine white blood cell counts and other hematological parameters based on sampling site. Inflamm Res. 2001; 50:523-527.
40. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation. 1997; 96:2953-2958.
41. Wang TJ. Significance of circulating troponins in heart failure: if these walls could talk. Circulation. 2007; 116:1217-1220.
42. Bressenot A, Marchal S, Bezdetnaya L, Garrier J, Guillemin F, Plenat F. Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma. J Histochem Cytochem. 2009; 57:289-300.
43. Porter AG, Jänicke RU. Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 1999; 6:99-104.
44. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005; 4:147-171.
45. Zhang Y, Wang Y, Gupta P, Chen Z. Multidrug Resistance Proteins (MRPs) and Cancer Therapy. AAPS J. 2015:1-11.
46. Gajewski TF, Schreiber H, Fu Y. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013; 14:1014-1022.
47. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P. Culprit and victim-DNA topoisomerase II. Lancet Oncol. 2002; 3:235-243.
48. Stravopodis DJ, Karkoulis PK, Konstantakou EG, Melachroinou S, Lampidonis AD, Anastasiou D, Kachrilas S, Messini-Nikolaki N, Papassideri IS, Aravantinos G. Gradedependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines. Int J Oncol. 2009; 34:137-160.
49. Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013; 73:2412-2417.
50. Duggan ST, Keating GM. Pegylated liposomal doxorubicin. Drugs. 2011; 71:2531-2558.
51. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987; 47:936-942.
52. Chen L, Liang Y, Ruan J, Ding Y, Wang X, Shi Z, Gu L, Yang X, Fu L. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. J Pharm Pharmacol. 2004;56:1061-1066.
53. Tiwari AK, Sodani K, Dai CL, Abuznait AH, Singh S, Xiao ZJ, Patel A, Talele TT, Fu L, Kaddoumi A, Gallo JM, Chen ZS. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer letters. 2013; 328: 307-317.
54. Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 2008; 68:7905-7914.
55. Kathawala RJ, Wei L, Anreddy N, Chen K, Patel A, Alqahtani S, Zhang YK, Wang YJ, Sodani K, Kaddoumi A, Ashby CR Jr, Chen ZS. The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. Oncotarget. 2015; 6:510-521. doi:10.18632/oncotarget.2638.